Fig. 62 (abstract P360).
The therapeutic effects of IL-2 complex with peptide vaccine. a-e C57BL/6 mice were inoculated with B16F10 melanoma cells (5 x 105 cells/mouse). After 7 days, mice received BiVax twice (day 7 and 12). IL-2 complexCD122 or IL-2 complexCD25 was administered on day 12, 14, and 16. a The mean sizes of tumor and (b) the overall survival of tumor-bearing mice are depicted. c The percentage of Trp1-tetramer+ cells in CD8+ T cells was examined on day 18 and 31. d The representative image of vitiligo at the tumor-inoculated lesion in the mouse, which received BiVax and IL-2 complexCD25 (day 30). e The expression of PD-1 on Trp1-tetramer+ CD8+ T cells was assessed on day 31. Results are presented as mean ± SD. (*p<0.05, n.s.: not significant)